HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin

References

• Kannel, W. B., Castelli, W. P. and Gordon, T. (1979). Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study. Ann. Int. Med., 90, 85–91.
   PubMed Web of Science ®Google Scholar
• Castelli, W. P. (1998). Cholesterol and lipids in the risk of coronary artery disease. The Framingham Heart Study. Can. J. Cardiol., 4 (Suppl A), 5A–10A.
   Google Scholar
• Assmann, G. and Schulte, H. (1992). Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (The PROCAM experience). Am. J. Cardiol., 70, 733–737.
   PubMed Web of Science ®Google Scholar
• Assmann, G., Cullen, P. and Schulte, H. (1998). The Munster Heart Study (PROCANI). Results of follow-up at 8 years. Eur. Heart J., 19 (Suppl A), A2–A11.
   PubMedGoogle Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (1993). Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA, 269, 3015–3023.
   PubMed Web of Science ®Google Scholar
• Second Joint Task Force of European and other Societies on Coronary Prevention (1998). Prevention of coronary heart disease in clinical practice. Eur. Heart J., 19, 1434–1503.
   PubMed Web of Science ®Google Scholar
• Wood, D. (1998). European and American recommendations for coronary heart disease prevention. Eur. Heart J., 19, Al2–A19.
   Google Scholar
• Wood, D., Durrington, P., Poulter, N., McInnes, G., Rees, A. and Wray, R. on behalf of the Societies' Joint British recom-mendations on prevention of coronary heart disease in clinical practice. Heart, 80 (Suppl 2), S1–29.
   Google Scholar
• Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Theroux, P., Warnica, J. W., Arnold, J. M., Nash, D. T., Wun, C. C., Davis, B. R., Hawkins, C. M. and Braunwald, E. (1996). The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1001–1009.
   PubMed Web of Science ®Google Scholar
• The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 339, 1349–1357.
   PubMed Web of Science ®Google Scholar
• West of Scotland Coronary Prevention Study Group (1998). Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation, 97, 1440–1445.
   PubMed Web of Science ®Google Scholar
• Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W. and Gotto, A. M. Jr for the AFCAPS/TexCAPS Research Group (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA, 279, 1615–1622.
   PubMed Web of Science ®Google Scholar
• Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B. and Dawber, T. R. (1977). High-density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med., 62, 707–714.
   PubMed Web of Science ®Google Scholar
• Patsch, W. and Gotto, A. M. Jr (1995). High-density lipoprotein cholesterol, plasma triglyceride, and coronary heart disease: pathophysiology and management. Adv. Pharmacol., 32, 375–426.
   PubMedGoogle Scholar
• Brewer, H. B., Santamarina-Fojo, S. M. and Hoeg, J. M. (1996). Genetic dyslipo-proteinemias. In: Atherosclerosis and Coronary Artery Disease (Eds Fuster, V., Ross, R. and Topol, E. J.), Lippincott-Raven Publishers, Philadelphia, pp. 69–88.
   Google Scholar
• Tall, A. R. (1998). An overview of reverse cholesterol transport. Eur. Heart J., 19 (Suppl A), A31–A35.
   PubMedGoogle Scholar
• von Eckardstein, A. and Assmann, G. (1998). High density lipoproteins and reverse cholesterol transport: lessons from mutations. Atherosclerosis, 137 (Suppl A), S7–S11.
   PubMedGoogle Scholar
• Milionis, H. J., Elisaf, M. S. and Mikhailidis, D. P. (1999). Platelet function and lipid lowering interventions. Platelets, 10, 357–367.
   PubMed Web of Science ®Google Scholar
• Rifkind, B. M. (1990). High-density lipoprotein cholesterol and coronary artery disease: survey of the evidence. Am. J. Cardiol., 66, 3A–6A.
   PubMed Web of Science ®Google Scholar
• Gordon, D. J., Knoke, J., Probstfield, J. L., Superko, R. and Tyroler, H. A. for the Lipid Research Clinics Program (1986). High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinic's Coronary Primary Prevention Trial. Circulation, 74, 1217–1225.
   PubMed Web of Science ®Google Scholar
• Manninen, V, Elo, M. O., Frick, M. H., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Mdenpäd, H., Mälkönen, M., Mänttdri, M., Norola, S., Pasternack, A., Pikkarainen, J., Romo, M., Sjöblorn, T. and Nikki E. A. (1988). Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA, 260, 641–651.
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383–1389.
   PubMed Web of Science ®Google Scholar
• Pedersen, T. R., Olsson, A. G., Faergeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyördld, K., Miettinen, T., Christophersen, B., Tobert, J. A., Musliner, T. A. and Cook, T. J. for the Scandinavian Simvastatin Survival Study Group (1998). Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 97, 1453–1460.
   PubMed Web of Science ®Google Scholar
• Rubins, H. B., Robins, S. J., Collins, D., Andersen, J. W., Elam, M. B., Faas, R H., Linares, E., Schaefer, E. J., Schectman, G., Wilt, T. J. and Wittes, J. T. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med., 341,410–418.
   PubMed Web of Science ®Google Scholar
• Bruckert, E., De Gennes, J. L., Malbecq, W. and Baigts, F. (1995). Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clin. Cardiol., 18, 621–629.
   PubMed Web of Science ®Google Scholar
• Shepherd, J. (1995). Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur. Heart J., 16, 5–13.
   PubMed Web of Science ®Google Scholar
• Durrington, P. N. (1998). Can we afford to treat hyperlipidaemia as we should? Strategies for rational treatment. Athero-sclerosis, 139 (Suppl 1), S1–S5.
   PubMedGoogle Scholar
• Amsterdam, E. A. and Deedwania, P. C. (1998). A perspective on hyperlipidemia: concepts of management in the prevention of coronary artery disease. Am. J. Med., 105, 69S–74S.
   PubMedGoogle Scholar
• Stein, E. A., Lane, M. and Laskarzewski, P. (1998). Comparison of statins in hyper-triglyceridemia. Am. J. Cardiol., 81 (Suppl 4A), 66B–69B.
   PubMed Web of Science ®Google Scholar
• Brown, A. S., Bakker-Arkema, R. G., Yellen, L., Henley, R. Jr, Guthrie, R., Campbell, C. R, Koren, M., Woo, W., McClain, R. and Black, D. M. (1998). Treating patients with documented atherosclerosis to National Cholesterol Education Program - recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J. Am. Cardiol., 32, 665–672.
   Web of Science ®Google Scholar
• Jones, P., Kafoneck, S., Laurora, I. and Hunninghake, D. for the CURVES Investigators (1998). Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hyper-cholesterolemia (The CURVES Study). Am. J. Cardiol., 81, 582–587.
   PubMed Web of Science ®Google Scholar
• Wierzbicki, A. S., Lumb, P. J., Semra, Y. K., Chik, G., Christ, E. R., Crook, M. A. (1999). Efficacy of atorvastatin- compared with simvastatin-based therapies in the management of severe familial hyper-lipidaemias. Quart. J. Med., 92, 387–394.
   Google Scholar
• Wierzbicki, A. S., Lumb, P. J., Chik, G. and Crook, M. A. (1999). Comparison of therapy with simvastatin 80 mg or atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int. J. Clin. Pract., 53, 609–611.
   PubMed Web of Science ®Google Scholar
• Wierzbicki, A. S., Lumb, P. J., Chik, G. and Crook, M. A. (2000). High-density lipoprotein cholesterol and triglyceride response with simvastatin-vs.-atorvastatin in familial hypercholesterolemia. Am. J. Cardiol., in press.
   PubMed Web of Science ®Google Scholar
• Crouse, J. R. III, Frolich, J., Ose, L., Mercuri, M. and Tobert, J. A. (1999). Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am. J. Cardiol., 83, 1476–1477.
   PubMed Web of Science ®Google Scholar
• Davidson, M. H., Plotkin, D., Hunninghake, D., Stein, E. A., Bays, H., Dujovne, C. A., Keilson, L. M., Korenman, S. G., Weiss, S. R., Robertson, D. G., Stepanavage, M. and Mercuri, M. (1998). Efficacy of simvastatin 40 and 80-mg/day in combined hyper-lipidemia. Thirteenth International Symposium on Drugs Affecting Lipid Metabolism (DALM), Florence, May 30-June 2, Abstracts, p. 78.
   Google Scholar
• Furberg, C. D., Herrington, D. M. and Psaty, B. M. (1999). Are drugs within a class interchangeable? Lancet, 354, 1202–1204.
   PubMed Web of Science ®Google Scholar
• Gotto, A. M., Whitney, E., Stein, E. A., Shapiro, D. R., Clearfield, M., Weis, S., Jou, J. Y. et al. (2000). Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/ Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation, 101, 477–484.
   PubMed Web of Science ®Google Scholar
• White, C. M. (1999). Pharmacological effects of HMG CoA reductase inhibitors other than lipid metabolism. J. Clin. Phannacol., 39, 111–118.
   Web of Science ®Google Scholar
• Rosenson, R. S. and Tangney, C. C. (1998). Anti-atherothrombotic properties of statins. JAMA, 279, 1643–1650.
   PubMed Web of Science ®Google Scholar
• Wierzbicki, A. S., Lumb, P. J., Semra, Y. K. and Crook, M. A. (1998). Effects of atorvastatin on plasma fibrinogen. Lancet, 351, 591–592.
   Google Scholar
• Nair, D. R., Papadakis, J. A., Jagroop, I. A., Mikhailidis, D. P. and Winder, A. R (1998). Statins and fibrinogen. Lancet, 351, 1430.
   PubMed Web of Science ®Google Scholar
• Wierzbicki, A. S., Crook, M. A., Nair, D., Mikhailidis, D. P. and Winder, A. R (2000). More on statins and fibrinogen. Atherosclerosis, 148, 204.
   PubMed Web of Science ®Google Scholar
• Milionis, H. J., Elisaf, M. S. and Mikhailidis, D. P. (2000). Treatment of dyslipidaemias in patients with established vascular disease: a review of the fibrates. Gum Med. Res. Opin., 16(1), 21–32.
   PubMed Web of Science ®Google Scholar